TSFVIT03:	Subjects With Maximum On-treatment Diastolic Blood Pressure by Category of Blood Pressure; Safety Analysis Set (Study jjcs - core)						
 	Active Study Agent 	Active Study Agent 	 	Risk Difference (%) (95% CI) 	Risk Difference (%) (95% CI) 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	Xanomeline High Dose vs Placebo 	Xanomeline Low Dose vs Placebo 	
Diastolic Blood Pressure (mmHg), n (%) 	N=53 	N=73 	N=59 	  	  	
N 	53 	70 	58 	 	 	
<60 	6 (11.3%) 	8 (11.4%) 	9 (15.5%) 	-4.2 (-16.8, 8.4) 	-4.1 (-16.0, 7.8) 	
≥60 to 89 	47 (88.7%) 	61 (87.1%) 	48 (82.8%) 	5.9 (-7.0, 18.9) 	4.4 (-8.1, 16.9) 	
≥90 to 109 	0 	1 (1.4%) 	1 (1.7%) 	-1.7 (-5.1, 1.6) 	-0.3 (-4.6, 4.1) 	
≥110 to 119 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
≥120 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	

Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation. 	
Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation.